# To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes

> **NCT03950505** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 60 (estimated)

## Conditions studied

- Non-alcoholic Steatohepatitis
- Type2 Diabetes

## Interventions

- **DRUG:** Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks

## Key facts

- **NCT ID:** NCT03950505
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-29
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950505, "To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03950505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*